Cystathionine β-Synthase Inhibition Is a Potential Therapeutic Approach to Treatment of Ischemic Injury

Citation

Published Version
doi:10.1177/1759091415578711

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:15034896

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
Cystathionine β-Synthase Inhibition Is a Potential Therapeutic Approach to Treatment of Ischemic Injury

Su Jing Chan1, Chou Chai2, Tze Wei Lim1, Mie Yamamoto1, Eng H Lo3, Mitchell Kim Peng Lai1, and Peter Tsun Hon Wong1

Abstract
Hydrogen sulfide (H2S) has been reported to exacerbate stroke outcome in experimental models. Cystathionine β-synthase (CBS) has been implicated as the predominant H2S-producing enzyme in central nervous system. When SH-SY5Y cells were transfected to overexpress CBS, these cells were able to synthesize H2S when exposed to high levels of enzyme substrates but not substrate concentrations that may reflect normal physiological conditions. At the same time, these cells demonstrated exacerbated cell death when subjected to oxygen and glucose deprivation (OGD) together with high substrate concentrations, indicating that H2S production has a detrimental effect on cell survival. This effect could be abolished by CBS inhibition. The same effect was observed with primary astrocytes exposed to OGD and high substrates or sodium hydrosulfide. In addition, CBS was upregulated and activated by truncation in primary astrocytes subjected to OGD. When rats were subjected to permanent middle cerebral artery occlusion, CBS activation was also observed. These results imply that in acute ischemic conditions, CBS is upregulated and activated by truncation causing an increased production of H2S, which exacerbate the ischemic injuries. Therefore, CBS inhibition may be a viable approach to stroke treatment.

Keywords
cystathioine β-synthase, hydrogen sulfide, homocysteine, cysteine, oxygen glucose deprivation, stroke

Introduction
Hydrogen sulfide (H2S) has been known as a toxic gas for more than a century due to its reversible inhibition of cytochrome c oxidase (Beauchamp et al., 1984; Reiffenstein et al., 1992; Dorman et al., 2002). In recent years, it has been recognized that H2S functions as a signaling molecule in the central nervous system (CNS), involving in the regulation of ion channels, neurotransmitter functions, and other intracellular signaling molecules such as tyrosine kinases (Abe and Kimura, 1996; Tan et al., 2010; Liu et al., 2012). Current evidence suggests that H2S is predominantly produced in the CNS by cystathionine β-synthase (CBS) using cysteine (Cys) and homocysteine (Hcy) as substrates (Abe and Kimura, 1996; Chen et al., 2004; Singh et al., 2009). CBS is heme and pyridoxal-5'-phosphate dependent. It is predominantly expressed in astrocytes (Enokido et al., 2005; Lee et al., 2009) but has also been reported to be expressed in Purkinje cells and Ammon’s horn neurons (Robert et al., 2003).

Cys has been reported as a risk factor for coronary heart disease (Xiao et al., 2011), while Hcy is known as a risk factor for stroke (Hankey, 2006). A prospective study showed that total Hcy concentration was significantly higher in stroke cases than in controls (geometric
mean 13.7 vs. 11.9 μM; Perry et al., 1995). Interestingly, high Hcy concentration in blood of ischemic stroke patients is associated with a negative influence on stroke outcome (Pniewski et al., 2003). Similarly, high plasma Cys levels on admission before treatment also correlated significantly with poor clinical outcome assessed at 3 months post stroke (Wong et al., 2006). These findings implicated a clinical relevance of Hcy and Cys in ischemic stroke outcome. In addition, Cys is a substrate for γ-glutamylcysteine synthetase, which catalyzes the first reaction in the biosynthesis of glutathione (GSH), a major cellular antioxidant known to protect cells from oxidative damage mainly through the action of GSH peroxidase (Cohen and Hochstein, 1963; Meister and Anderson, 1983). This reaction is ATP dependent and therefore GSH will be depleted following ATP depletion. This may contribute to an increase in Cys level under ischemic conditions.

In animal studies, Qu et al. (2006) reported that H$_2$S was increased in the cerebral cortex at 24 hr after permanent middle cerebral artery occlusion (pMCAO), a rat stroke model. The H$_2$S level was further increased by Cys administration. Pretreatment with Cys increased the infarct volume following pMCAO, while the inhibition of H$_2$S synthesis by CBS inhibitors reduced infarct volume. Moreover, sodium hydrosulfide (NaHS, an H$_2$S donor) could mimic the effects of Cys pretreatment. These results suggested that in ischemia, H$_2$S production increases through increased availability of Cys and increased H$_2$S worsens ischemic injuries, based on both histological and functional assessments (Qu et al., 2006). Therefore, suppression of H$_2$S production via the inhibition of CBS activity may be an attractive approach to improve stroke outcome during the acute phase of ischemic stroke. However, inhibition studies were performed using nonselective inhibitors of CBS (Asimakopoulou et al., 2013). An often used inhibitor, aminooxyacetic acid (AOAA) also inhibits cystathioine γ-lyase (CSE) and other enzymes like γ-aminobutyric acid (GABA) transaminase (Loscher, 1981). Furthermore, the possibility of pleiotropic effects of these inhibitors in influencing stroke outcome cannot be entirely ruled out.

In order to further establish if the overproduction of endogenous H$_2$S leads to enhanced cell death under ischemic conditions, we overexpressed CBS in undifferentiated neuroblastoma SH-SY5Y cells. Enhanced cell death was observed when the cells were subjected to oxygen and glucose deprivation (OGD) in the presence of Cys and Hcy. The same was then observed in primary astrocytes albeit to a lesser extent. In addition, we found that OGD rapidly increased the expression of CBS in primary astrocytes and in rat brains subjected to pMCAO. Hence, we provide evidence that upregulation of CBS expression exacerbates the outcome of stroke most likely through increased H$_2$S production.

**Methods**

**Ethics Statement**

All animal experimental procedures in this study were approved by the Institutional Animal Care and Use Committee of the National University of Singapore.

**Cell Culture**

Neuroblastoma SH-SY5Y cell line was obtained from American Type Culture Collection (ATCC). Cell were maintained in Dulbecco’s modified Eagle’s medium (DMEM)/F12 (Gibco, Invitrogen, USA) containing 10% fetal bovine serum (FBS; Gibco, Invitrogen, USA) and 1% penicillin–streptomycin (Gibco, Invitrogen, USA) at 37°C and incubated in a humidified atmosphere with 95% air/5% CO$_2$.

**Primary Culture of Rat Cortical Astrocyte**

Primary astrocyte cultures were prepared from the cerebral cortices of 1- to 2-day old Sprague-Dawley rat pups as described previously (Lu et al., 2008) with minor modifications. Briefly, the cerebral cortices were harvested and digested with 0.25% trypsin (Gibco, Invitrogen, USA) at 37°C. The cells were seeded onto poly-L-lysine-coated flask with DMEM/F12 (Gibco, Invitrogen, USA) medium supplemented with 10% FBS (Gibco, Invitrogen, USA) and 1% penicillin–streptomycin (Gibco, Invitrogen, USA). The cultures were maintained at 37°C in a humidified atmosphere with 95% air/5% CO$_2$. Culture medium was replaced 72 hr later and changed medium twice weekly thereafter. At 10 to 12 days, the confluent cultures were shaken overnight to minimize microglia contamination. The remaining astrocyte monolayers were cultured until Day 21.

**Construction of Rat CBS Lentiviral Expression Vectors**

Total RNA was isolated from rat PC12 cells using RNeasy Mini Kit (Qiagen). First-strand cDNA was synthesized from total RNA using the RevertAid H Minus First Strand cDNA Synthesis Kit (Fermentas/Thermo Scientific). CBS coding region was isolated by polymerase chain reaction (PCR) from the cDNA using PrimeStar GXL DNA Polymerase (Clontech) with a SalI site-containing forward (5’ CGCGTCGACCATG CCTTCAGGGACATCC 3’) and BamH1 site-containing reverse (GCGGATCTATTCCCAGGTTCTGCTCAC) primers. Amplified product was digested with SalI and BamH1 and inserted in-frame 3’ to a myc-tag sequence in pL6mCWmycIE lentiviral vector to
gene was visualized by EGFP fluorescence. Addition of 1\% O2/5\% CO2/94\% N2 for 24 hr at 37°C with 1\% streptomycin/penicillin in a hypoxia chamber and without CBS overexpression in glucose-free DMEM was needed, antibiotic selection was applied by adding Blasticidin S (Invitrogen) at a final concentration of 1\%.

**Lentivirus Particle Production and Cell Transduction**

Lentivirus packaging was performed in 293FT cells according to the protocol provided with the ViraPower™ Lentiviral Directional TOPO® Expression Kit (Invitrogen). Lentivirus particles were harvested from cell culture supernatant according to the protocol of Deiseroth Lab (http://www.stanford.edu/group/dlab/resources/lvprotocol.pdf). Lentivirus harboring the CBS expression constructs was used to transduce undifferentiated SH-SY5Y cells. Prior to transduction, cells were cultured to 90\% confluence. Concentrated virus particle was added to cell culture medium containing 8\,\mu g/ml of Polybrene (Sigma Aldrich). Where long-term expression of transgene was needed, antibiotic selection was applied by adding Blasticidin S (Invitrogen) at a final concentration of 10\,\mu g/ml to the medium. Expression of transgene was visualized by EGFP fluorescence.

**Oxygen and Glucose Deprivation**

OGD was achieved by incubating the SH-SY5Y cells with and without CBS overexpression in glucose-free DMEM with 1\% streptomycin/penicillin in a hypoxia chamber (1\% O2/5\% CO2/94\% N2) for 24 hr at 37°C in a humidified incubator. OGD for primary cortical astrocyte culture was achieved by incubating the primary astrocytes in glucose-free DEMEM with 1\% streptomycin/penicillin in a hypoxia chamber (5\% CO2/95\% N2) from 0.5 to 8 hr at 37°C in a humidified incubator. For NaHS treatment, primary astrocytes were seeded onto 96-well plate overnight. The regular medium was replaced with OGD medium supplemented with vehicle or NaHS at 100 or 300\,\mu M. Cell viability was measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (0.5\,mg/ml, 2.5 hr) with formazan solubilized in 100\% dimethylsulfoxide (DMSO) and absorbance determined at 570 nm using a microplate reader (Sunrise; TECAN) after 3 to 72 hr. Rat brains tissues from sham-operated control and pMCAO were lysed by RIPA buffer (Cell Signaling) supplemented with protease inhibitor and phosphatase inhibitor cocktail (Roche, Mannheim, Germany). Absorbance was converted to H2S concentration through a standard curve obtained by using NaHS as the standard.

**Western Blot**

Brains tissues from sham-operated control and pMCAO (3 to 72 hr) rats were lysed by RIPA buffer (Cell Signaling) supplemented with protease inhibitor and phosphatase inhibitor cocktail (Roche, Mannheim, Germany).
SH-SY5Y cells and primary cortical astrocytes were lysed by CST buffer (Cell Signaling) supplemented with protease inhibitor and phosphatase inhibitor cocktail (Roche, Manheim, Germany). Total protein was determined by Bradford protein assay (Biorad, CA, USA). Proteins were separated by 10% SDS/PAGE, transferred onto a polyvinylidene difluoride (PVDF) membrane (Amersham Biosciences, Buckinghamshire, UK), and then blocked with 10% nonfat milk. The membrane was then incubated with antibodies against CBS, or β-actin (Cell Signaling Technologies, Beverly, MA, USA) at 4°C overnight, then washed and incubated in HRP-conjugated anti-rabbit or mouse IgG at room temperature for 1 hr. Visualization was carried out using Luminata Forte or Crescendo western HRP substrate (Millipore Corporation, Billerica, MA, USA), and the chemiluminescence signals were detected using UVIchemi (UVItec, Cambridge, UK).

**Immunofluorescence for Brain Slices**

Rats were anaesthetized and perfused with 0.1 mol/L phosphate buffer saline followed by 4% paraformaldehyde through the heart. Brains were removed and immersed in 4% paraformaldehyde overnight at 4°C. Paraformaldehyde-fixed brains were then cryoprotected in 10% sucrose and eventually 20% sucrose at 4°C until use. Coronal sections (30 μm) were made using a cryostat and mounted on glass slides (Matsunami, Japan). Nonspecific binding was blocked by incubating the section in 5% goat serum for 1 hr at room temperature. Antibodies against CBS (1:200) was used and incubated at 4°C overnight. Sections were then rinsed and incubated with Alexa 488-conjugated goat anti-rabbit (Molecular probes, USA) secondary antibody for 1 hr at room temperature. Fluorescent-labeled sections were mounted using ProLong gold antifade reagent (Life technologies, USA). Fluorescent images were captured using QImaging (Canada), and images captured were processed by Image Pro insight (QImaging, Canada).

**Statistical Analysis**

All comparisons were performed by one-way analysis of variance (ANOVA) followed by post hoc analysis with Bonferroni correction or by two-tailed independent t test using IBM SPSS Statistics 19. Data are expressed as mean±SEM. Statistical significance is reached when p < .05.

**Results**

**CBS Overexpression in SH-SY5Y Cells**

Under normal conditions, SH-SY5Y cells express CBS at a very low level. However, they can be efficiently transduced with lentiviral vector to overexpress CBS together with EGFP, a fluorescent reporter. Results shown in Figure 1 confirmed that these transduced cells strongly express both EGFP and CBS (Figure 1(a) and 1(b)). The full-length 63 kDa isoform was detected by Western blot but not the truncated 45-kDa isoform (Figure 1(b)), indicating that the truncation mechanism may not be in place in these cells. When CBS substrates (Cys + Hcy) were added to cell homogenates, H2S was produced in a concentration-dependent manner (Figure 1(c)). These results indicate that the CBS artificially overexpressed in these cells are fully functional. As 0.1 mM Cys + 0.01 mM Hcy are reportedly close to physiological concentrations (Singh et al., 2009; Stipanuk and Ueki, 2011), these concentrations were used as the low substrate condition and a 10-fold increase as the high substrate condition in subsequent experiments.

**Effects of H2S Production on Cell Viability**

CBS-overexpressing (CBSOE) cells did not show any difference in cell viability on exposure to high or low substrate concentrations when compared with control cells as shown by the MTT assay (Figure 2(a)). However, when cells are subjected to OGD, cell death increased markedly regardless of substrate conditions. In the absence or presence of low substrates, cell viability fell to about 30% to 40% in both cell types whether or not CBS was overexpressed. In the presence of high substrates, cell viability was about 30% in the control cells but about 5% in the CBSOE cells, indicating a significant
increase in cell death. When LDH release was measured under the same conditions, the results were entirely consistent with the MTT assay results (Figure 2(b)).

The enhanced cell death observed in CBSOE cells when exposed to high substrate condition was attenuated concentration in a concentration-dependent manner by the addition of AOAA, a nonselective CBS inhibitor, immediately after the addition of substrates (Figures 2(c) and (d)). At 0.5 mM of AOAA, complete reversal was achieved in the MTT assay, while only partial reversal was observed in LDH release assay. These data strongly support the notion that elevated production of H2S in cells subjected to high substrate conditions enhanced cell death when the cells were subjected to OGD.

We next examined the effects of OGD in primary rat astrocytes under different substrate conditions. Consistent with the findings in CBSOE SH-SY5Y cells, primary astrocytes subjected to OGD under high concentrations of Cys + Hcy showed cell viability of about 64% by MTT assay, a significant decrease from about 77% in cells not exposed to substrates (Figure 3(a)). This is supported by a threefold increase in LDH release (Figure 3(b)). A small but significant increase in LDH release was also observed in control cells exposed to the high substrate condition without OGD, as opposed to no effects observed by MTT assay. This may be due to toxicity attributable to Cys directly (Janaky et al., 2000) or indirectly (Nath and Salahudeen, 1993). To see if these effects could be mediated by H2S, we added NaHS at 300 mM and observed a significant decrease in cell viability in primary astrocytes when subjected to OGD (Figures 3(c) and (d)).

### Upregulation of CBS Expression and Infarct Volume Following Ischemic Insults

CBS expression in primary astrocytes was found to increase rapidly in rat brains within 30 min after the onset of OGD and remained high for at least 3 hr (Figure 4). However, unlike CBSOE SY-SH5Y cells, Western blot results demonstrated the presence of both the full-length and truncated isoforms (63 and 45 kDa, respectively) of CBS.

The cortex and striatum are the most affected regions following pMCAO in rats (Liu et al., 2009). Western blot analysis revealed that the truncated but not the full-length CBS was markedly upregulated (about twofold)
in the cortex at 8 hr after pMCAO (Figures 5(a) and (b)). Similarly, truncated CBS expression was upregulated (sevenfold) in the striatum but at a later time point of 24 hr post-pMCAO (Figures 6(a) and (b)). Immunofluorescent staining (which does not distinguish the full length from the truncated form) results were consistent with the Western blot data, showing an upregulation of total CBS expression (Figures 5(c) and 6(c)). CBS in both regions was largely expressed in astrocytes based on colocalization with GFAP staining, while colocalization of CBS and NeuN was not observed (Figures 5(d) and 6(d)).

In view of the different time course of CBS expression following pMCAO in the cortex and striatum, the infarct volumes in these two brain regions were determined at 8 and 24 hr post-pMCAO. It was observed that the infarct volume in the striatum was significantly larger at 24 hr than that at 8 hr (27% vs. 12%). In contrast, the infarct volume in the cortex as well as the whole affected hemisphere was not significantly different between the two
time points (Figure 7). This shows that the ischemic inju-
ries continued to develop significantly between 8 and
24 hr post-pMCAO in the striatum but not in the
cortex. Therefore, the peaking of CBS expression in the
striatum at 24 hr may appear to be associated with the
extent of ischemic injury.

Discussion

H2S can be produced in the body by three key enzymes,
namely CBS, CSE, and 3-mercaptopuruvate sulfurtrans-
ferase (3-MST, in combination with cysteine aminotrans-
ferase; Kashfi and Olson, 2013). CSE is expressed
predominantly in the cardiovascular system (Zhao
et al., 2001; Tang et al., 2013) but at low levels in the
brain and therefore generally accepted as a minor player,
if at all, in H2S production in the brain (Abe and Kimura,
1996). 3-MST is widely present in the brain, but its
physiological relevance is not clearly understood.
However, in a recent study, Zhao et al. (2013) reported
that 3-MST was downregulated in both the cortex and
striatum following pMCAO, hence mitigating its role in
increased production of H2S under ischemic conditions
(Zhao et al., 2013). Therefore, the focus is on CBS as the
predominant enzyme responsible for H2S production in
the brain.

The native CBS enzyme is a tetramer consisting of four
subunits of 63 kDa (551 amino acids). This subunit can
be cleaved in its C-terminal region at Arg413 to yield
a 45-kDa subunit that lacks the regulatory domain.
Two truncated subunits form a dimer that is about twice as active as the tetramer (Kery et al., 1998; Majtan et al., 2014). In primary astrocytes subjected to OGD, the expression of the 63-kDa CBS was clearly upregulated (Figure 4(b)), and the truncated form increased within 30 min. Similarly, the truncated form also increased in both the cortex and striatum within 24 hr post-pMCAO (Figures 5 and 6). These observations demonstrated that CBS responds very rapidly to ischemic insults. In contrast to primary astrocytes, the full-length 63-kDa CBS in the cortex and striatum remained unchanged following pMCAO as shown by Western blotting (Figures 5(a) and 6(a)). This difference may be caused by the high basal expression in the cortex and striatum as opposed to very low basal level of CBS expression in the primary astrocytes. However, the increased level of the 45-kDa CBS implies an upregulation of the expression of the 63-kDa CBS. This is supported by the observed increase in immunostaining for CBS (Figures 5(c) and 6(c)). Therefore, it appears that increased CBS expression and activation may underlie the increased production of $\text{H}_2\text{S}$ in ischemia (Qu et al., 2006). The mechanism that triggers the activation by cleavage remains to be elucidated. However, it has been reported that tumor necrosis factor-$\alpha$ (TNF-$\alpha$) induced CBS cleavage in HepG2 cells (Zou and Banerjee, 2003). This could be examined further as inflammatory cytokines such as TNF-$\alpha$ were found to be increased under ischemic conditions (Zhou et al., 2013). It is possible that increased CBS truncation causes a corresponding increase in the expression of the full-length enzyme by a positive feedback mechanism. It is noted that the truncated form was not detected in the SH-SY5Y CBSOE cells, indicating that cleavage of CBS does not occur or occurs only at very low level (Figure 1(b)) in cells that do not endogeneously express CBS, perhaps due to the lack of the truncation mechanism. These cells can serve as a model to investigate the factors that induce cleavage and thus activation of CBS.

Hyperhomocysteinemia is an independent risk factor for stroke (Perry et al., 1995).
elevated after stroke, and raised Hcy levels adversely affect cerebral infarction after stroke (Spence, 2007). In animal studies, Cys has been reported to increase in animal ischemic model, and Cys administration also increases the ischemic damage after stroke (Slivka and Cohen, 1993; Wong et al., 2006). Thus, there is ample evidence to suggest that in acute stroke, CBS activation is accompanied by a high availability of substrates for H_{2}S production, which is most efficiently produced by \( \beta \)-replacement reaction where Cys condenses with Hcy to produce H_{2}S (Chen et al., 2004; Singh et al., 2009). Taken together, it may be concluded that the acute ischemic conditions are conducive for markedly elevated production of H_{2}S. We mimicked such conditions by overexpressing CBS in SH-SY5Y neuroblastoma cells and observed a massive increase in H_{2}S production when the overexpressing cells were exposed to high substrate conditions but not substrate concentrations that may reflect normal physiological conditions (Singh et al., 2009; Stipanuk and Ueki, 2011). While Hcy and Cys can be neurotoxic to cells at high concentrations (Kruman et al., 2000; Poddar et al., 2001; Jara-Prado et al., 2003; Wong et al., 2006; Hosoi et al., 2010; Koz et al., 2010), the high concentrations used in these experiments were clearly nontoxic as no effects on cell viability were observed in both control or CBSOE cells. In addition, we had similarly overexpressed CBS in HEK293 cells, which are originated from the kidney. The same results were obtained in these cells as in the CBSOE SH-SY5Y cells (data not presented), indicating that the

**Figure 5.** CBS expression in the cerebral cortex after pMCAO. (a) Representative Western blot results on CBS expression at 3 to 24 hr post-pMCAO in the cerebral cortex. (b) Densitometry measurement of CBS expression over 24 hr after pMCAO. Protein expression is expressed relative to the ipsilateral control C. Data are presented as mean ± SEM, \( n = 3–4 \). ANOVA for CBS 63 kDa on the ipsilateral side: \( F(3, 12) = 0.608, p = .623 \). ANOVA for CBS 45 kDa on the ipsilateral side: \( F(3, 8) = 6.702, p < .05; \#p < .05 \) against ipsilateral control by Bonferroni; **\#p < .005** against the contralateral side by independent \( t \) test. (c) Immunofluorescent staining of CBS showed increased CBS expression in the cortex 8 hr after pMCAO (a) compared with sham-control rats (b). Scale bar: 200 \( \mu \)m. (c) shows the location where the CBS immunofluorescent photomicrographs were taken. (d) Colocalization of CBS (green) and GFAP (red, top panel) and lack of colocalization of CBS (green) and NeuN (red, bottom panel) in the cortex at 8 hr after pMCAO. Scale bar: 50 \( \mu \)m. CBS = cystathionine \( \beta \)-synthase; pMCAO = permanent middle cerebral artery occlusion; ANOVA = analysis of variance.
presence of a high concentration of H$_2$S would enhance cell death under ischemic conditions in cells of neural or nonneural origin.

The mechanism by which H$_2$S enhances cell death under ischemic conditions requires thorough investigations. It is known to inhibit cytochrome c oxidase, carbonic anhydrase, monoamine oxidase, cholinesterase, and Na$^+$/K$^+$-ATPase (Szabo, 2007); as well as to potentiate glutamate excitotoxicity (Cheung et al., 2007; Chen et al., 2011). Using mature mouse cortical neurons expressing functional glutamate receptors, Cheung et al. (2007) reported that glutamate-induced cell death was exacerbated by the addition of NaHS. They further reported that NaHS at concentrations < 200 µM induced apoptosis, while at concentrations > 200 µM, necrosis was induced. In contrast, Kimura and Kimura (2004) reported that H$_2$S at 100 µM concentration reversed cell death in immature mouse cortical neuron treated with 1 mM glutamate (Kimura and Kimura, 2004). These findings suggest that H$_2$S may have neuroprotective effects at lower range of concentrations but become cytotoxic at a higher range of concentrations (Dorman et al., 2002). In our experiments, we did not observe any protective effects under the low substrate conditions (Figures 2 and 3). This may be due to the low concentrations of H$_2$S that we used in our experiments or the selectivity of H$_2$S protective effect for excitotoxic but not ischemic insults.
In vivo, under ischemic conditions, excitotoxicity is more important because the failure of the energy-dependent glutamate reuptake process leads to extracellular accumulation of glutamate. However, such glutamate accumulation is more unlikely in vitro, so excitotoxicity is likely less important (Wang et al., 2002). OGD causes energy depletion in cells, thus interrupting ATP-dependent processes notably the Na\(^+\)/K\(^+\)-ATPase and eventually disruption of ion gradients across the cellular membrane. This causes cell membrane depolarization leading to Ca\(^2+\) overload (Wang et al., 2002) and cell death by necrosis and apoptosis (Orrenius et al., 1994; Kristian et al., 1998), involving the generation of free radicals (Abramov et al., 2007), mitochondrial or endoplasmic reticulum dysfunction (Kristian et al., 1998,) and caspase activation (Chong et al., 2012). Interestingly, the truncated CBS has also been reported to be able to generate superoxide radicals as it has reduction potential similar to other hemethiolate proteins such as chloroperoxidase, cytochrome P450, and nitric oxide synthase (Carballal et al., 2008). We are currently investigating how H\(_2\)S may interact with the cell death mechanisms following OGD using the CBSOE cells.

H\(_2\)S has also been reported to be cytoprotective (Calvert et al., 2010) under various other conditions. First, NaHS was reported to protect primary cortical neurons (Kimura and Kimura, 2004), primary microglia (Hu et al., 2007), and primary astrocytes (Lu et al., 2008). In these studies, glutamate, lipopolysaccharide, and hydrogen peroxide (H\(_2\)O\(_2\)), respectively, were used to induce cell injuries. In cultured cell lines, NaHS is reportedly protective against cell damage induced by A\(_\beta\) (Tang et al., 2008), rotenone (Hu et al., 2009), 6-hydroxydopamine (6-OHDA; Tiong et al., 2010; Xie et al., 2012), and 1-methyl-4-phenylpyridinium (MPP\(^+\); Yin et al., 2009). In the in vivo setting, protective effects has been reported against global cerebral ischemia (Ren et al., 2010), and transient MCAO (Wang et al., 2014). These may indicate differences between ischemic models with and without reperfusion. Overall, it appears that the effects of H\(_2\)S in ischemia may vary according to prevailing conditions, mechanism of the injury-inducing agent, and concentrations of H\(_2\)S. To our knowledge, no protective effects have been reported against OGD in in vitro studies. Much work is needed to provide further understanding.

While it has been reported previously that administration of NaHS worsened stroke outcome in animal studies (Qu et al., 2006), we have further provided strong evidence that endogenously produced H\(_2\)S could enhance cell death under ischemic conditions. Therefore, the present results may support the idea that CBS is a viable therapeutic target, and CBS inhibition may hold promise as a treatment of ischemic stroke. However, currently available CBS inhibitors lack selectivity and are therefore not suitable for in vivo investigations. More selective CBS inhibitors will be needed for further progress.

**Summary**

Cystathionine β-synthase (CBS) is the predominant enzyme responsible for the increased hydrogen sulfide (H\(_2\)S) production under ischemic conditions. High H\(_2\)S levels leads to enhanced cell death both in vitro and in vivo. CBS may be a potential therapeutic target for the treatment of stroke.
Acknowledgements
Authors are grateful to Professor Hideo Kimura (National Institute of Neuroscience, Japan) for the gift of anti-CBS antibody; Mrs. Ting Wee Lee for her administrative support.

Author Contributions
SJC, CC, MY, MKPL, EHL and PTHW contributed to experimental design. SJC, TWL, CC and MY performed experiments. SJC and PTHW performed data analysis. SJC, CC, MY, MKPL, EHL and PTHW contributed to manuscript preparation.

Declarations of Conflicting Interests
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
This work was funded by a grant from the Biomedical Research Council (BMRC 01/121/19/169) awarded to PTHW.

References
and hypersensitivity to excitotoxicity. *Journal of Neuroscience*, 20, 6920–6926.


